09 marzo 2017

Yondelis Combinado con Avelumab ( Anticuerpo de Pfizer / Merck ) van a Iniciar Fase I-II de la Mano del National Cancer Institute EEUU (NCI) como Colaborador y como Sponsor el Fred Hutchinson Cancer Research Center .

Sponsor : Fred Hutchinson Cancer Research Center.

Collaborator National Cancer Institute (NCI).

ClinicalTrials Identifier: NCT03074318
Updated: 2017_03_07 .

Descriptive Information
Brief title
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery .

Official title
A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma .

Brief summary
This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as avelumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and trabectedin may work better in treating patients with liposarcoma or leiomyosarcoma.